N-arylsulfonamide-based adenosine analogues to target RNA cap N7-methyltransferase nsp14 of SARS-CoV-2 - Archive ouverte HAL Access content directly
Journal Articles RSC Medicinal Chemistry Year : 2024

N-arylsulfonamide-based adenosine analogues to target RNA cap N7-methyltransferase nsp14 of SARS-CoV-2

Abstract

RNA cap methylations have been shown to be crucial for the life cycle, replication, and infection of ssRNA viruses, as well as for evading the host's innate immune system. Viral methyltransferases (MTases) therefore represent an attractive target for the development of compounds as tools and inhibitors. In coronaviruses, N7methyltransferase function is localized in nsp14, which has become an increasingly important therapeutic target with the COVID-19 pandemic. In recent years, we have been developing SAH-derived bisubstrates with adenosine and an N-arylsulfonamide moiety targeting both SAM and RNA binding sites in nsp14. We report here the synthesis of 31 SAH analogues with the N-arylsulfonamide attached to the 5'-position of adenosine via different linkers such as N-ethylthioether, N-ethylsulfone, N-ethylamino or N-methyltriazole. The compounds were obtained efficiently by amine sulfonylation or click chemistry. Their ability to inhibit SARS-CoV-2 N7-MTase was evaluated and the best inhibitors showed a submicromolar inhibitory activity against N7-MTase nsp14.
Fichier principal
Vignette du fichier
RSC Med Chem 2024.pdf (637.69 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-04426066 , version 1 (30-01-2024)

Identifiers

Cite

Rostom Ahmed‐belkacem, Joris Troussier, Adrien Delpal, Bruno Canard, Jean-Jacques Vasseur, et al.. N-arylsulfonamide-based adenosine analogues to target RNA cap N7-methyltransferase nsp14 of SARS-CoV-2. RSC Medicinal Chemistry, 2024, ⟨10.1039/d3md00737e⟩. ⟨hal-04426066⟩
23 View
14 Download

Altmetric

Share

Gmail Facebook X LinkedIn More